Western firms show growing interest in traditional Chinese medicine

03/27/2013 | China Daily (Beijing)

Pharmaceutical firms from Europe, Japan, South Korea and the United States are investing in the development of medications and treatments derived from traditional Chinese medicine. GlaxoSmithKline, for example, recently announced a traditional Chinese medicine program based in Shanghai that will target both a Chinese and global market. "Our priority is to transform TCM from an experience-based practice to evidence-based medicines through innovation and differentiation," said Jingwu Zang, head of R&D for GlaxoSmithKline in China.

View Full Article in:

China Daily (Beijing)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA